Pi3 Kinase Inhibitors, Idelalisib, Duvelisib, & Copanlisib

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Pi3 Kinase Inhibitors, Idelalisib, Duvelisib, & Copanlisib at Lymphoma & Myeloma on October 18, 2018.